Inovio Pharmaceuticals, Inc.
A maker of DNA-based vaccines and medicines that teach the body's own cells to fight disease. The company designs synthetic DNA instructions and delivers them with its hand-held CELLECTRA device, whose brief electrical pulses open tiny pores in cells to target cancers and HPV-related conditions. Founded in 1983 as Biotechnologies & Experimental Research, it later operated as Genetronics and took its current name after acquiring the Norwegian gene-delivery firm Inovio in 2005.
Granted 171.8K
Granted 10.2K
Granted 47.3K
Granted 53.5K
Granted 48.3K
Granted 4.3K
Granted 4.3K
Granted 4.3K
Granted 4.3K
Granted 5.3K
Granted 4.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Shea Jacqueline ElizabethChief Executive Officer, Director · 24 transactions | -51.1% | 111.0K | 171.8K | — | — |
| Weiner David B.Director · 8 transactions | -90.6% | 87.6K | 10.2K | — | — |
| Humeau LaurentChief Scientific Officer · 20 transactions | -79.2% | 49.0K | 47.3K | — | — |
| Kies PeterCFO · 20 transactions | -80.2% | 47.9K | 53.5K | — | — |
| Sumner Michael JohnChief Medical Officer · 15 transactions | +20.1% | 42.0K | 48.3K | — | — |
| Benito Simon XDirector · 2 transactions | -87.1% | 12.2Kas of May 2025 | 4.3K | — | — |
| Yarno Wendy LDirector · 2 transactions | -85.8% | 10.5Kas of May 2025 | 4.3K | — | — |
| Miller Ann CalbyDirector · 2 transactions | -85.2% | 9.9Kas of May 2025 | 4.3K | — | — |
| Shepard JayDirector · 2 transactions | -84.3% | 9.2Kas of May 2025 | 4.3K | — | — |
| Dansey Roger DDirector · 3 transactions | -79.3% | 8.9Kas of May 2025 | 5.3K | — | — |
| Zoth Lota S.Director · 2 transactions | -83.4% | 8.7Kas of May 2025 | 4.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.